Relation of factor V leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery

Annals of Internal Medicine

Volumn 128, Issue 4, 1998, Pages 270-276

  Ryan, Daniel H ^a   Crowther, Mark A ^b   Ginsberg, Jeffrey S ^b   Francis, Charles W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENOTYPE; HUMAN; INCIDENCE; JOINT SURGERY; KNEE ARTHROPLASTY; MALE; PHLEBOGRAPHY; POINT MUTATION; PRIORITY JOURNAL; RISK ASSESSMENT; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME;

EID: 0032520087     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-4-199802150-00003     Document Type: Article

References (47)

1. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-7.
2. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA. 1994;91:1396-400.
3. Dahlbäck B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis. 1994;24:139-51.
4. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-6.
5. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost. 1995;74:449-53.
6. Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest. 1994;94:923-7.
7. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-8.
8. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343:1535-6.
9. Zoller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536-8.
10. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-7.
11. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2.
12. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031-5.
13. Brenner B, Zivelin A, Lanir N, Greengard J, Griffin JH, Seligsohn U. Hereditary thrombophilia as a multigenic disease: increased thrombotic risk due to combined hereditary heterozygous protein C deficiency and activated protein C resistance. Thromb Haemost. 1995;73:942.
14. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-7.
15. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173:210-3.
16. Aslam S, Standen GR, Morse C, Scott GL. DVT following oral contraceptive therapy in association with homozygous factor V Leiden [Letter]. Clin Lab Haematol. 1995;17:99-100.
17. Claggett GP, Anderson FA Jr, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism. Chest. 1992;102:391S-407S.
18. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994;271:1780-5.
19. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;329:1370-6.
20. Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment. Arch Intern Med. 1993;153:2221-8.
21. Clagett GP. Prevention of postoperative venous thromboembolism: an update. Am J Surg. 1994;168:515-22.
22. Francis CW, Pellegrini VD Jr, Marder VJ, Totterman S, Harris CM, Gabriel KR, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992;267:2911-5.
23. Francis CW, Pellegrini VD Jr, Leibert KM, Totterman S, Azodo MV, Harris CM, et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost . 1996;75:706-11.
24. Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991;114:545-51.
25. Levine MN, Gent M, Hirsh J, Weitz J, Turpie AG, Powers P, et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch Intern Med. 1996;156:851-6.
26. Ginsberg JS, Brill-Edwards P, Panju A, Patel A, McGinnis J, Smith F, et al. Pre-operative plasma levels of thrombin-antithrombin III complexes correlate with the development of venous thrombosis after major hip or knee surgery. Thromb Haemost 1995;74:602-5.
27. Francis CW, Pellegrini VD Jr, Totterman S, Boyd AD, Marder VJ, Leibert KM, et al. Prevention of venous thrombosis after hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg. 1997:79A:1365-72.
28. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg. 1972;104:134-44.
29. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ. 1995;311:1145-8.
30. Dawson-Saunders B, Trapp RG. Basic and Clinical Statistics. Norwalk, CT: Appleton & Lange; 1990.
31. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Espérance B, Demers C, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med. 1996;124:619-26.
32. Colwell CW Jr, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA Jr, Ritter MA. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop. 1995;321:19-27.
33. Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F, et al. Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost. 1992;67:417-23.
34. Fauno P, Suomalainen O, Rehnberg V, Hansen TB, Kroner K, Soimakallio S, et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. J Bone Joint Surg Am. 1994;76:1814-8.
35. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft für Thrombose- und Hämostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol. 1996;16:742-8.
36. Lensen RP, Rosendaal FR, Koster T, Allaart CF, de Ronde H, Vandenbroucke JP, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood. 1996;88:4205-8.
37. Otterson GA, Monahan BP, Harold N, Steinberg SM, Frame JN, Kaye FJ. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med. 1996;101:406-12.
38. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vase Biol. 1995;15:783-5.
39. Desmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet. 1996;347:1374-5.
40. Biousse V, Piette JC, Frances C, Bletry O, Papo T, Tournier-Lasserve E, et al. Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506→Gln mutation [Letter]. J Rheumatol. 1995;22:1215.
41. Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis. Thromb Haemost. 1995;74:1255-8.
42. Lee DH, Walker IR, Poon MC, Rivard G, Teitel J, Ritchie B, et al. Factor V Leiden is not predictive in severe hemophilia [Abstract]. Haemophilia. 1996; 2:47.
43. Wells PS, Lensing AW, Davidson BL, Prins MH, Hirsh J. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis. Ann Intern Med. 1995; 122:47-53.
44. Whitehouse G. Radiological diagnosis of deep vein thrombosis [Editorial]. Br Med J (Clin Res Ed). 1987;295:801-2.
45. Agnelli G, Ranucci V, Veschi F, Rinonapoli E, Lupattelli L, Nenci GG. Clinical outcome of orthopaedic patients with negative lower limb venography at discharge. Thromb Haemost. 1995;74:1042-4.
46. Scurr JH, Coleridge-Smith PD, Hasty JH. Deep venous thrombosis: a continuing problem [Editorial]. BMJ. 1988;297:28.
47. Davidson HC, Mazzu D, Gage BF, Jeffrey RB. Screening for deep venous thrombosis in asymptomatic postoperative orthopedic patients using color Doppler sonography: analysis of prevalence and risk factors. AJR Am J Roentgenol. 1996;166:659-62.